Back to Stakeholders
Psy Therapeutics is a Cambridge, MA-based drug discovery company developing novel small-molecule NCEs for neuropsychiatric and neurological disorders. Founded around 2019 by MGH psychiatrists Jerry Rosenbaum, Roy Perlis, and Maurizio Fava with Brant Binder, the company applies DNA-encoded library screening (via X-Chem) and validated CNS targets. Pipeline includes PSY-05 (anxiety), PSY-06 (MDD), PSY-02 (dementia/tau aggregation), and programs in Parkinson's and chronic pain. Non-hallucinogenic, psychedelic-inspired CNS approach.
Drug Pipeline
3PSY-06
Discovery
Novel NCE for major depressive disorder. Lead optimization stage.
PSY-02
Discovery
Tau aggregation inhibitor targeting Alzheimer's disease and related neurodegenerative disorders.
Quick Facts
- Type
- Private Biotech
- Founded
- 2019
- Lead Stage
- Discovery
- Website
- Visit